The pharmaceutical company Moderna announced Wednesday that US health authorities had finally agreed to review the application for authorization of its new flu vaccine.
This reversal comes a week after the US Food and Drug Administration (FDA) rejected the review of this mRNA vaccine, much to the laboratory's astonishment.
According to Moderna, which had publicly deplored this decision, the US federal authorities considered its clinical trial insufficient.
The company explains that it has since had a "constructive" meeting with the FDA and received assurances that its application would be reviewed. However, the application has been revised, and the laboratory has committed to conducting an additional study, according to a press release.
The FDA's initial refusal had sent shockwaves through the pharmaceutical industry, already alarmed by the anti-vaccine policies of US Health Secretary Robert Kennedy Jr.
English 
French